Quick Facts

• Relief of Symptoms: Treats nausea and vomiting.
• Maximum Duration: Treatment should generally not exceed one week.

---

Domperidone Wockhardt is used for the relief of symptoms of nausea and vomiting. These conditions are characterized by the sensation of feeling sick or the forceful expulsion of stomach contents. The medication works by increasing the movement of the stomach and upper digestive tract, which helps food move along more quickly. This action is considered beneficial in controlling the symptoms of feeling sick.

While the medicine has historically been used for other gastrointestinal discomforts, its current use is focused strictly on the management of nausea and vomiting symptoms.

It is important to note that the treatment duration should be limited. To minimize potential risks, the medication is to be used at the lowest effective dose for the shortest possible time, typically not exceeding a maximum of one week for nausea and vomiting relief.

Regulatory References

1. EMA therapeutic overview

Who Can and Cannot Use Domperidone Wockhardt?

The population eligibility for using this medicine is strictly defined by regulatory authorities and is based on age, underlying health conditions, and concomitant medication.

Contraindicated Populations (Must Not Use)

Domperidone is contraindicated and must not be used in patients with the following conditions:

• Known existing prolongation of cardiac conduction intervals (e.g., QTc interval) or underlying heart diseases, such as congestive heart failure.
• Moderate or severe hepatic (liver) impairment.
• Conditions where stimulation of gastric motility could be harmful (e.g., gastrointestinal haemorrhage, mechanical obstruction, or perforation).
• Concurrently taking most QT-prolonging drugs or potent CYP3A4 inhibitors.
• Significant electrolyte disturbances (e.g., low potassium or magnesium levels).

Age and Conditional Eligibility

• Allowed Use: Officially permitted for adults and adolescents aged 12 years and older who weigh mathbf35 kg or more.
• Not Recommended: Use in children younger than 12 years or adolescents weighing less than 35 kg is no longer licensed for the approved indication.
• Conditional Use: Patients with severe renal impairment require a reduction in dosing frequency. Use in individuals over 60 years of age requires caution due to an observed higher risk of serious ventricular arrhythmias.
• Pregnancy and Lactation: Use during pregnancy should only be considered when justified by the anticipated therapeutic benefit. The medicine is not recommended during breastfeeding as it is excreted in human milk.

Interactions with other medicines and products

Official regulatory information for Domperidone Wockhardt establishes significant restrictions based on two primary interaction domains: metabolic interference and cardiac conduction risk.

Contraindicated Combinations

Co-administration of Domperidone is formally contraindicated with specific medicinal products due to the potential for clinically significant interactions.

• Potent CYP3A4 Inhibitors: These substances, such as systemic azole antifungals (e.g., ketoconazole) and certain macrolide antibiotics (e.g., erythromycin, clarithromycin), are prohibited because they increase domperidone plasma exposure by inhibiting its primary metabolic clearance pathway, CYP3A4.
• QTc-Prolonging Medicinal Products: Co-administration with drugs that prolong the QTc interval (e.g., amiodarone, haloperidol, sotalol) is contraindicated due to an additive pharmacodynamic effect, raising the risk of serious ventricular arrhythmias.

Other Documented Interactions and Restrictions

Interaction Type	Requirement/Outcome
Timing-based	Antacids or antisecretory agents must not be taken simultaneously as they lower domperidone's oral bioavailability. Separation of administration is required.
Pharmacodynamic	Anticholinergic agents may antagonize the prokinetic effect of the medicine.
Population-specific	The medicine is contraindicated in patients with moderate or severe hepatic impairment due to substantially increased drug exposure.

These official restrictions define the safe boundary for co-administration, based entirely on label-documented pharmacokinetic and pharmacodynamic outcomes.

How Domperidone Wockhardt Works

The mechanism of action for Domperidone is rooted in its highly selective peripheral dopamine receptor antagonism. The molecule functions by blocking D2 and D3 dopamine receptors, specifically concentrating its activity on peripheral sites and the Chemoreceptor Trigger Zone (CTZ). This peripheral focus reflects the drug’s minimal penetration across the Blood-Brain Barrier (BBB), concentrating its influence on the autonomic regulation of the gut and the CTZ .

Action on Gastrointestinal Motility The mechanism leading to enhanced gastrointestinal motility involves blocking D2 receptors located on cholinergic nerve endings within the gut wall. Since dopamine typically acts to inhibit acetylcholine release, Domperidone’s antagonism removes this inhibition, thereby increasing acetylcholine concentration. This action results in increased, coordinated contractions (peristalsis) in the stomach and duodenum, and increased tension of the lower esophageal sphincter tone.

Modulation of the Chemoreceptor Trigger Zone (CTZ) Activity Domperidone modulates the central emetic input by antagonizing D2 receptors in the CTZ, a vulnerable area outside the BBB that acts as a primary chemical sensor for the vomiting center. By preventing the dopaminergic signal that triggers emetic pathway activation, the molecule increases the required level of stimulus for central vomiting reflex activation, thereby disrupting the signaling sequence.

The use of Domperidone Wockhardt is centered on the principle of using the lowest effective dose for the shortest necessary duration. The following information describes the standard administration and dosing for this medication.

---

Dosing and Route

The route of administration is oral, available in forms such as standard tablets, oral suspension, and orodispersible tablets (ODTs).

Population	Single Dose	Maximum Daily Dose	Frequency	Duration
Adults and Adolescents (12 years or more, 35 kg or more)	10 mg	30 mg	Up to 3 times per day	Typically 1 week or less

---

Administration Instructions

• Timing: Doses should be taken before meals or feeding. Taking the medicine after meals may delay its absorption.
• Frequency: A minimum interval of 8 hours must be observed between each 10 mg dose.
• Duration: The maximum treatment duration must generally not exceed one week.
• Missed Dose: If a dose is missed, it should be omitted, and the usual dosing schedule should be resumed. Do not take a double dose to compensate.
• Special Populations: For patients with severe renal impairment, the dosing frequency must be reduced to once or twice daily, depending on the severity of impairment, due to prolonged drug clearance.

Research evidence / Overview of studies for Domperidone Wockhardt

Evidence for the Relief of Symptoms of Nausea and Vomiting (Authorized Use)

Research exploring short-term symptom changes in adults primarily relies on Randomized Controlled Trials (RCTs) that compare the medicine against a placebo. These studies focus on outcomes related to physical discomfort, such as measuring changes in nausea intensity or monitoring the frequency of vomiting episodes over a defined time interval. The evidence research examined for the currently authorized indication is derived mainly from these short-term trials in adult populations.

Studies monitor how symptoms evolved in the observed adult populations. The findings describe patterns observed in these studies where patient-reported outcomes describing perceived discomfort were compared to those of the placebo group. Research has also explored its use in pediatric groups, specifically children aged 6 months to 12 years. However, findings from one large randomized study on this pediatric group indicated no observable difference in outcomes related to episodic or acute changes compared to placebo over 48 hours. This type of research contributes to understanding symptom patterns under specific, short-term research scenarios.

Long-Term Studies and Follow-up Duration

The majority of evidence research explored focuses on treatment periods of up to one week (7 days), relevant in trials assessing short-term or episodic symptom patterns. Regulatory reviews considered the evidence structure supporting the use of the medicine for symptom relief over this defined, limited period. Findings from the available research contributes to understanding short-term changes, but follow-up durations were limited and do not describe outcomes beyond this duration.

Long-term effects are not fully established. There is limited information for outcomes related to systemic or functional imbalance when the medicine was studied for extended periods. Data for long-term use in conditions previously studied, such as chronic dyspepsia, was determined to be insufficient to support continued authorization for those purposes.

Evidence in Special Populations

Research related to this medicine being studied in younger children has a Low certainty level assigned in official reviews, with findings were mixed and sample sizes were modest. Data for certain groups remain insufficient, and for children, a lack of consistent evidence and methodological limitations in studies led to the restriction of the authorized indication for this specific age group.

Conversely, older adults (aged 60 years and above) were observed in some post-marketing studies. These observational settings evaluated outcomes reflecting daily functioning or activity level and were primarily used by regulatory bodies to monitor real-world use and patterns related to physiological strain or stress in this group.

Key Studies & References

1. Domperidone: risks of cardiac side effects - GOV.UK Drug Safety Update (December 2014)
2. Domperidone for nausea and vomiting: lack of efficacy in children; reminder of contraindications in adults and adolescents - GOV.UK Drug Safety Update (December 2019)

Common questions about Domperidone Wockhardt (FAQ)

Q: Should Domperidone be taken with or without food?

Official administration instructions indicate that the medicine is typically taken before meals. Taking the medicine after eating may delay its absorption into the body, which could affect how quickly it begins to work.

---

Q: Is Domperidone safe to take during pregnancy or while breastfeeding?

Regulatory information states that use during pregnancy is conditional and should only be considered if the anticipated therapeutic benefit is deemed to outweigh the potential risk. Regarding breastfeeding, official documents indicate the medicine is excreted in human milk and is not generally recommended.

---

Q: How long is it safe to use Domperidone Wockhardt?

Official guidelines state that the maximum treatment duration should generally not exceed one week (7 days). This limitation is due to safety concerns, particularly regarding the risk of serious heart-related side effects. The lowest effective dose is to be used for the shortest possible duration.

---

Q: What color are the Domperidone Wockhardt tablets?

According to official product characteristics, Domperidone Wockhardt tablets are typically described as white or off-white. Patients are generally advised to confirm the appearance of their medicine with the dispensing pharmacist.

---

Q: What is the difference between Domperidone tablets and ODTs?

Domperidone is available in both standard tablets and Orally Dispersible Tablets (ODTs). The ODTs are specifically formulated to dissolve quickly in the mouth using saliva. This pharmaceutical form, Orally Dispersible Tablets (ODTs), is designed to offer an alternative administration method.

---

Q: Is Domperidone available generically?

Yes, the active ingredient, domperidone, is commonly available as a generic medicine in many countries where it is approved by local regulatory bodies like Health Canada and the MHRA.

---

Q: Can I get Domperidone over the counter?

No, in the UK and several other regions, Domperidone is now classified as a prescription-only medicine (POM). This change was implemented following regulatory reviews regarding the risk of serious cardiac side effects, meaning it must be dispensed under a valid prescription.

How to Store and Dispose of Domperidone Wockhardt?

The official storage and disposal guidelines for Domperidone Wockhardt ensure the product's stability and public safety.

Storage Requirements

Condition	Requirement (Official Labeling)
Temperature	Store tablets below 25, C (not refrigerated or frozen).
Protection	Protect the medicine from both light and moisture.
Container	Keep the medicine in its original container and in a closed condition.
Child Safety	Must be kept out of the sight and reach of children.
Stability	Oral suspension must be discarded six months after the first opening of the bottle.

Disposal Instructions

Unused or expired Domperidone must be handled as pharmaceutical waste. Do not throw away medicines via wastewater or household waste. Consult a pharmacist for guidance on disposing of the product according to local environmental regulations.